Zimmer Biomet Holdings Inc (NYSE:ZBH) – Cantor Fitzgerald issued their FY2017 earnings per share estimates for shares of Zimmer Biomet in a report released on Sunday, Zacks Investment Research reports. Cantor Fitzgerald analyst C. Bijou expects that the medical equipment provider will post earnings per share of $8.03 for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Zimmer Biomet’s FY2018 earnings at $8.15 EPS.
Several other research firms have also recently issued reports on ZBH. Royal Bank of Canada lowered their price objective on Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, November 7th. SunTrust Banks set a $136.00 target price on Zimmer Biomet and gave the company a “buy” rating in a report on Wednesday, November 1st. Morgan Stanley reduced their target price on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. BMO Capital Markets reduced their target price on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Finally, Deutsche Bank raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a report on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $137.42.
Zimmer Biomet (NYSE ZBH) opened at $121.68 on Wednesday. The stock has a market capitalization of $24,640.00, a PE ratio of 37.91, a PEG ratio of 1.90 and a beta of 1.15. Zimmer Biomet has a 1 year low of $108.03 and a 1 year high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company’s revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.79 earnings per share.
Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Nova Scotia Trust Co. purchased a new stake in Zimmer Biomet during the 3rd quarter valued at approximately $112,000. FNY Managed Accounts LLC purchased a new stake in Zimmer Biomet during the 3rd quarter valued at approximately $117,000. BB&T Investment Services Inc. purchased a new stake in Zimmer Biomet during the 2nd quarter valued at approximately $144,000. Steward Partners Investment Advisory LLC purchased a new stake in Zimmer Biomet during the 3rd quarter valued at approximately $140,000. Finally, Sandy Spring Bank raised its stake in Zimmer Biomet by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 66 shares during the last quarter. 86.06% of the stock is owned by hedge funds and other institutional investors.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is presently 29.91%.
TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Comments on Zimmer Biomet Holdings Inc’s FY2017 Earnings (NYSE:ZBH)” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://ledgergazette.com/2018/01/17/equities-analysts-offer-predictions-for-zimmer-biomet-holdings-incs-fy2017-earnings-zbh.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.